Cargando…

EGCG overcomes gefitinib resistance by inhibiting autophagy and augmenting cell death through targeting ERK phosphorylation in NSCLC

BACKGROUND: Several EGFR-tyrosine kinase inhibitors (TKIs), such as gefitinib (Gef), have been used as effective clinical therapies for patients with non-small cell lung cancer (NSCLC). However, due to acquired resistance, the efficacy of Gef treatment is severely blocked. Our preliminary study foun...

Descripción completa

Detalles Bibliográficos
Autores principales:	Meng, Jiao, Chang, Cuicui, Chen, Yuhua, Bi, Fangfang, Ji, Chen, Liu, Wei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2019
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6668247/ https://www.ncbi.nlm.nih.gov/pubmed/31440060 http://dx.doi.org/10.2147/OTT.S209441

Ejemplares similares

EGCG protects vascular endothelial cells from oxidative stress-induced damage by targeting the autophagy-dependent PI3K-AKT-mTOR pathway
por: Meng, Jiao, et al.
Publicado: (2020)

Combined treatment with N‐acetylcysteine and gefitinib overcomes drug resistance to gefitinib in NSCLC cell line
por: Li, Jun, et al.
Publicado: (2019)

Resveratrol overcomes gefitinib resistance by increasing the intracellular gefitinib concentration and triggering apoptosis, autophagy and senescence in PC9/G NSCLC cells
por: Zhu, Yinsong, et al.
Publicado: (2015)

Targeted Co-Delivery of Gefitinib and Rapamycin by Aptamer-Modified Nanoparticles Overcomes EGFR-TKI Resistance in NSCLC via Promoting Autophagy
por: Liu, Yuhong, et al.
Publicado: (2022)

Inhibition of DNA-PK by gefitinib causes synergism between gefitinib and cisplatin in NSCLC
por: Pan, Chi, et al.
Publicado: (2020)

Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance
por: Cretella, Daniele, et al.
Publicado: (2014)

Gefitinib upregulates death receptor 5 expression to mediate rmhTRAIL-induced apoptosis in Gefitinib-sensitive NSCLC cell line
por: Yan, Dong, et al.
Publicado: (2015)

Combining AKT inhibition with chloroquine and gefitinib prevents compensatory autophagy and induces cell death in EGFR mutated NSCLC cells
por: Bokobza, Sivan M., et al.
Publicado: (2014)

Curcumin overcome primary gefitinib resistance in non-small-cell lung cancer cells through inducing autophagy-related cell death
por: Chen, Ping, et al.
Publicado: (2019)

FOXO3 mutation predicting gefitinib-induced hepatotoxicity in NSCLC patients through regulation of autophagy
por: Guan, Shaoxing, et al.
Publicado: (2022)

Autophagy proteins regulate ERK phosphorylation
por: Martinez-Lopez, Nuria, et al.
Publicado: (2013)

Pilot study of radiofrequency hyperthermia in combination with gefitinib in gefitinib‐effective patients with advanced NSCLC
por: Qin, Yijia, et al.
Publicado: (2016)

EGCG induces human mesothelioma cell death by inducing reactive oxygen species and autophagy
por: Satoh, Motohiko, et al.
Publicado: (2013)

An EGCG Derivative in Combination with Nimotuzumab for the Treatment of Wild-Type EGFR NSCLC
por: Huang, Yanping, et al.
Publicado: (2023)

EGCG identified as an autophagy inducer for rosacea therapy
por: Zhou, Lei, et al.
Publicado: (2023)

Trifolium Flavonoids Overcome Gefitinib Resistance of Non-Small-Cell Lung Cancer Cell by Suppressing ERK and STAT3 Signaling Pathways
por: Wu, Zhiqiang, et al.
Publicado: (2020)

RNF25 promotes gefitinib resistance in EGFR-mutant NSCLC cells by inducing NF-κB-mediated ERK reactivation
por: Cho, Jung Hee, et al.
Publicado: (2018)

Shikonin sensitizes wild-type EGFR NSCLC cells to erlotinib and gefitinib therapy
por: Li, Yang-Ling, et al.
Publicado: (2018)

ABCC10 Plays a Significant Role in the Transport of Gefitinib and Contributes to Acquired Resistance to Gefitinib in NSCLC
por: Zhao, Hongbo, et al.
Publicado: (2018)

NVP-BEZ235 overcomes gefitinib-acquired resistance by down-regulating PI3K/AKT/mTOR phosphorylation
por: Sun, Zhihua, et al.
Publicado: (2015)

Fasudil Increased the Sensitivity to Gefitinib in NSCLC by Decreasing Intracellular Lipid Accumulation
por: Liao, Tingting, et al.
Publicado: (2022)

The mechanism of m(6)A methyltransferase METTL3-mediated autophagy in reversing gefitinib resistance in NSCLC cells by β-elemene
por: Liu, Shuiping, et al.
Publicado: (2020)

NEK7 Regulates NLRP3 Inflammasome Activation and Neuroinflammation Post-traumatic Brain Injury
por: Chen, Yuhua, et al.
Publicado: (2019)

Corrigendum: NEK7 Regulates NLRP3 Inflammasome Activation and Neuroinflammation Post-traumatic Brain Injury
por: Chen, Yuhua, et al.
Publicado: (2019)

Cucurbitacin D Overcomes Gefitinib Resistance by Blocking EGF Binding to EGFR and Inducing Cell Death in NSCLCs
por: Hong, Se Hyang, et al.
Publicado: (2020)

Losmapimod: A Novel Clinical Drug to Overcome Gefitinib-Resistance
por: Nishimura, Yukio
Publicado: (2018)

EGCG protects the mouse brain against cerebral ischemia/reperfusion injury by suppressing autophagy via the AKT/AMPK/mTOR phosphorylation pathway
por: Wang, Li, et al.
Publicado: (2022)

Exploring the relationship between autophagy and Gefitinib resistance in NSCLC by silencing PDLIM5 using ultrasound-targeted microbubble destruction technology
por: Zhang, Yao, et al.
Publicado: (2022)

Overcoming Resistance to Osimertinib by T790M Loss and C797S Acquisition Using Gefitinib in a Patient With EGFR-Mutant NSCLC: A Case Report
por: Enrico, Diego, et al.
Publicado: (2022)

Atorvastatin overcomes gefitinib resistance in KRAS mutant human non-small cell lung carcinoma cells
por: Chen, J, et al.
Publicado: (2013)

Synergistic induction of apoptosis by salinomycin and gefitinib through lysosomal and mitochondrial dependent pathway overcomes gefitinib resistance in colorectal cancer
por: Zou, Zheng-Zhi, et al.
Publicado: (2015)

The Dissociation of Gefitinib Trough Concentration and Clinical Outcome in NSCLC Patients with EGFR Sensitive Mutations
por: Xin, Shuang, et al.
Publicado: (2015)

Cerebral protection of epigallocatechin gallate (EGCG) via preservation of mitochondrial function and ERK inhibition in a rat resuscitation model
por: Qin, Sina, et al.
Publicado: (2019)

Ablation of caspase-1 protects against TBI-induced pyroptosis in vitro and in vivo
por: Liu, Wei, et al.
Publicado: (2018)

Emerging role of gefitinib in the treatment of non-small-cell lung cancer (NSCLC)
por: Tiseo, M, et al.
Publicado: (2010)

The Effect of Gefitinib on Treatment Necessity and Prognosis of NSCLC Patients with Early EGFR Mutations
por: Song, Ruiqiang, et al.
Publicado: (2022)

Inhibition of GPR30 sensitized gefitinib to NSCLC cells via regulation of epithelial-mesenchymal transition
por: Yang, Xiaomin, et al.
Publicado: (2023)

244-MPT overcomes gefitinib resistance in non-small cell lung cancer cells
por: Zhang, Yi, et al.
Publicado: (2015)

Co-delivery of Gefitinib and chloroquine by chitosan nanoparticles for overcoming the drug acquired resistance
por: Zhao, Liang, et al.
Publicado: (2015)

A meta-analysis of the safety and effectiveness of pemetrexed compared with gefitinib for pre-treated advanced or metastatic NSCLC
por: Lu, Xiaoxin, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_t4ifvgroi8qsi9f52e7rf22o70